MedPath

Oxytocin's Effect on the Advantageous- and Disadvantageous-inequity

Not Applicable
Completed
Conditions
Healthy
Interventions
Drug: Intranasal placebo
Registration Number
NCT06405737
Lead Sponsor
University of Electronic Science and Technology of China
Brief Summary

The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and whether oxytocin has similar effects on them or not.

Detailed Description

The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and its underlying neural mechanisms and whether oxytocin has similar effects on them or not. A double-blinded, placebo-controled, between-subject design is employed in this study. In a randomized order, a total of 80 healthy males are instructed to self-administrated intranasal spray of oxytocin or placebo. A modified inequity decision-making task starts 45 minutes after treatment with behavioral (fairness rating, preference rating and the choice rate of unequal option) and fMRI data being collected during this task. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ), Behavioral Inhibition System and Behavioral Activation System Scale (BIS/BAS). Subjects are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before and after the task.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
80
Inclusion Criteria
  • Healthy subjects without past or current psychiatric or neurological disorders
Exclusion Criteria
  • history of head injury
  • pregnant,menstruating,taking oral contraceptives
  • medical or psychiatric illness.
  • excessive head movement (> 3mm) during scanning

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
placeboIntranasal placeboa single dose of 24 international units (IU) of placebo will be administered with 3 puffs of treatment to each nostril.
oxytocinIntranasal oxytocina single dose of 24 international units (IU) of OT will be administered with 3 puffs of treatment to each nostril.
Primary Outcome Measures
NameTimeMethod
Behavioral index: fairness rating scores45-75 minutes after treatment administration

Participants are instructed to rate their perceived levels of fairness to the allocation using a 9-point Likert scale within 4 seconds (1 = very unfair, 9 = very fair).

Behavioral index: preference rating scores45-75 minutes after treatment administration

Participants are instructed to rate their perceived levels of preference to the allocation using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very preferable).

Neural indices: fMRI-based measures of the outcome presentation stage45-75 minutes after treatment administration

Functional magnetic resonance imaging (fMRI) is employed to assess participants' blood-oxygen-level dependent signals when they are confronted with monetary allocations (advantageous-inequity, disadvantageous-inequity, and fair).

Secondary Outcome Measures
NameTimeMethod
Behavioral index: choice rate of unequal option45-75 minutes after treatment administration

Participants are instructed to make a hypothetical choice between the actual allocation in the current trial and the other fair option if they were given another chance to re-choose.

Neural indices: fMRI-based measures of outcome and re-decision stages45-75 minutes after treatment administration

Functional magnetic resonance imaging (fMRI) is employed to assess participants' blood-oxygen-level dependent signals when they are instructed to make a hypothetical choice between the actual allocation in the current trial and the other fair option if they were given another chance to re-choose.

Trial Locations

Locations (1)

University of Electronic Science and Technology of China (UESTC)

🇨🇳

Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath